Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

Summary

This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male volunteers and Japanese participants with moderate to severe atopic dermatitis.

Timeline

Start

2020-01-13

Primary completion

2020-03-14

Completion

2020-12-18

Outcome

Outcome not reported

Stopped: “Company decision of termination of the clinical program.”

Drugs

Indications